[{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces the U.S. Launch of the First Generic Version of THIOLA\u00ae (tiopronin) Tablets","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Tiopronin Delayed-Release Tablets Launch For Cystinuria Treatment","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches Tiopronin Delayed-Release Tablets, Generic Version of THIOLA EC\u00ae","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Endo Pharm","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Endo Pharm \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Endo Pharm \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for 2-[[(2R)-2-sulfanylpropanoyl]amino]acetic acid

2-[[(2R)-2-sulfanylpropanoyl]amino]acetic acid
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

2-[[(2R)-2-sulfanylpropanoyl]amino]acetic acid

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

11 API Suppliers, 7 USDMF, 1 JDMF, 2 EU WC, 7 NDC API, 5 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

FINISHED DOSAGE FORMULATIONS

18 FDF Dossiers, 12 FDA Orange Book, 6 Europe

RELATED EXCIPIENT COMPANIES

1 Evonik, 4 SPI Pharma, 3 DKSH, 1 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 1 Pfanstiehl, 1 Actylis, 1 Aeon Procare, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 9 BASF, 8 Corel Pharma Chem, 2 Gangwal Chemicals, 4 Kerry, 1 Kima Chemical, 6 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 2 Pluviaendo, 1 Prachin Chemical, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

18 Fillers, Diluents & Binders, 16 Coating Systems & Additives, 10 Direct Compression, 9 Taste Masking, 9 Controlled & Modified Release, 8 Lubricants & Glidants, 7 Solubilizers, 7 Film Formers & Plasticizers, 7 Granulation, 5 Co-Processed Excipients, 4 Thickeners and Stabilizers, 3 Disintegrants & Superdisintegrants, 3 Parenteral, 3 Chewable & Orodispersible Aids, 2 Coloring Agents, 1 Emulsifying Agents

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 12 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 6 Finished Drug Prices

MARKET PLACE

7 APIs, 3 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 US Patents, 3 US Exclusivities

REF. STANDARDS & IMPURITIES

1 Others

1 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Endo Pharm

Ireland

World Dairy Expo 2024

Not Confirmed

02

Cycle Pharmaceuticals

United Kingdom

World Dairy Expo 2024

Not Confirmed

03

Teva Pharmaceutical Industries

Israel

World Dairy Expo 2024

Not Confirmed